Research graph
References from Mavacamten for Obstructive HCM in Malignancy With Life-Threatening Symptoms. Local targets link to admitted publications; unresolved targets remain external evidence.
2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines
10.1016/j.jacc.2020.08.045 · 2020 · External reference
2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)
10.1093/eurheartj/ehad194 · 2023 · External reference
Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy during active chemotherapy
2026 · External reference
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)31792-x · 2020 · External reference
Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial
10.7326/m18-3016 · 2019 · External reference
Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy
10.1016/j.jacc.2020.03.064 · 2020 · External reference
Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy
10.1016/j.jacc.2022.04.048 · 2022 · External reference
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
10.1093/eurheartj/ehac244 · 2022 · External reference
